Observational Study of ASCVD Risks of Type 2 Diabetes in East China (NCT04866667) | Clinical Trial Compass
CompletedNot Applicable
Observational Study of ASCVD Risks of Type 2 Diabetes in East China
China316 participantsStarted 2021-05-01
Plain-language summary
The aim of this study is to screen patients with type 2 diabetes with high risk of cardiovascular disease, and intervene with or without Glucagon like peptide-1 receptor agonists.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Type 2 diabetes
* HbA1c ≥7.0%
* Prior CVD cohort: age ≥50 and ≥1 of the following criteria.
* Prior MI
* Prior stroke or TIA
* Prior coronary, carotid or peripheral arterial revascularization
* N50% stenosis of coronary, carotid, or lower extremity arteries
* History of symptomatic CHD documented by Positive exercise stress test or any cardiac imaging or Unstable angina with ECG changes
* Asymptomatic cardiac ischemia Documented by positive nuclear imaging test, exercise test or dobutamine stress echo
* Chronic heart failure NYHA class II-III
* Chronic renal failure, eGFR \<60 mL/min per 1.73m2 MDRD eGFR \<60 mL/min per Cockcroft-Gault formula
* No Prior CVD group: Age ≥60 y and ≥1 of the following criteria.
* Microalbuminuria or proteinuria
* Hypertension and left ventricular hypertrophy by ECG or imaging
* Left ventricular systolic or diastolic dysfunction by imaging
* Ankle-brachial index b0.9
Exclusion Criteria:
* Type 1 diabetes
* other type diabetes
* Calcitonin ≥50 ng/L
* Use of a GLP-1 receptor agonist (exenatide, liraglutide or other) or pramlintide or any DPP-4 inhibitor within the 3 months prior to screening
* Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Shortterm use of other insulin during this period in connection with intercurrent illness is allowed, at Investigators discretion
* Acute decompensation of glycemic control
* An …